A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW 2009/2010 injected intramuscularly in young adults (18 to 60 years) and in elderly (over 60 years).

Trial Profile

A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW 2009/2010 injected intramuscularly in young adults (18 to 60 years) and in elderly (over 60 years).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.
    • 21 Jul 2009 Actual patient number (118) added as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top